Concord Medical Files 2021 Annual Report on Form 20-F
BEIJING, April 30, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual...
Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights
HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% of Cellenkos, Inc ("CLNK") and the rights to develop and commercialize all of its existing and future...
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma Hikma Pharmaceuticals PLC...
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that an clinical trial abstract related to ATG-008/onatasertib has been selected for presentation in the upcoming...
Biocytogen Enters into Antibody Agreement with Merck
BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development...
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for cancer treatment. Under this agreement, IONOVA will...
The unrecognised return on investment of creating children from assisted reproduction
SINGAPORE, April 29, 2022 /PRNewswire/ -- A serious decline in world population numbers and its major economic and social ramifications in coming decades can be addressed by recognition of the life-long benefits generated by children born from assisted reproduction. This was the thrust of a keynote address today to the 2022 Congress...
New IFPA report reveals link between psoriatic disease and mental health
STOCKHOLM, April 29, 2022 /PRNewswire/ -- Psoriatic disease is an inflammatory illness that affects the skin and joints. Itchy, flaky patches of skin are perhaps the most common symptom. But psoriatic disease goes far deeper. For many, one of the most difficult challenges in living with psoriatic disease is its heavy impact on...
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Greater sense of patient empowerment with telemedicine trends in IVF services
SINGAPORE, April 29, 2022 /PRNewswire/ -- Telemedicine that became a vital engagement tool between health professionals and patients during the COVID-19 pandemic is emerging as a welcome new treatment of choice among fertility clinics and couples striving for parenthood. Patients seeking assisted conception services, such as IVF, are increasingly interacting by telephone and...
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting
SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology ("2022 ASCO Annual Meeting"). The abstracts are...
